4. Renal denervation
Medtronic paid over $1 billion for Ardian in 2010. The startup’s renal denervation technology — stimulating renal nerves to reduce drug-resistant hypertension — hit several significant snags, but Martha expects Medtronic will be filing for FDA approval in the fall if current OnMed clinical trials are successful. The FDA issued breakthrough device designation for renal denervation, so the technology would automatically qualify for four years of reimbursement upon FDA approval (if the Biden administration upholds the policy implemented by the former Trump administration).
Martha said Medtronic hopes to present the results at TCT in the fall.